Lingling Miao

Lingling Miao

Auto-generated profile, based on publicly available information

Lingling Miao

Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2018 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
MPMengfan Pu
Mengfan Pu
JCJing Chen
Jing Chen
ZTZhouteng Tao
Zhouteng Tao
LMLingling Miao
Lingling Miao
XQXinming Qi
Xinming Qi
JRJin Ren
Jin Ren

26 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MGMan Gao
Man Gao
LMLingling Miao
Lingling Miao
MLMingxia Liu
Mingxia Liu
CLChenggang Li
Chenggang Li
CYCunzhi Yu
Cunzhi Yu
JRJin Ren
Jin Ren
MiR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1 miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1

1 April 2016 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
LMLingling Miao
Lingling Miao
HYHailan Yao
Hailan Yao
CLChenggang Li
Chenggang Li
MPMengfan Pu
Mengfan Pu
XYXuan Yao
Xuan Yao
YWYizheng Wang
Yizheng Wang

1 November 2017 in Cancer Letters
Verified
Journal Article
Closed access
YZYang Zhao
Yang Zhao
XQXinming Qi
Xinming Qi
JCJing Chen
Jing Chen
WWWenxin Wei
Wenxin Wei
CYCunzhi Yu
Cunzhi Yu
JRJin Ren
Jin Ren

29 July 2013 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
XQXin-Ming Qi
Xin-Ming Qi
LMLing-Ling Miao
Ling-Ling Miao
YCYan Cai
Yan Cai
LGLikun Gong
Likun Gong
JRJin Ren
Jin Ren

19 September 2016 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
CLCheng-Gang Li
Cheng-Gang Li
MPMeng-Fan Pu
Meng-Fan Pu
CLChun-Zhu Li
Chun-Zhu Li
MGMan Gao
Man Gao
MLMing-Xia Liu
Ming-Xia Liu
JRJin Ren
Jin Ren
Previous studies have shown that microRNA-1304 (miR-1304) is dysregulated in certain types of cancers, including non-small cell lung cancer (NSCLC), and might be involved in tumor survival and/or growth. In this study we investigated the direct target of miR-1304 and its function in NSCLC in vitro. Human lung adenocarcinoma cell lines (A549 and NCI-H1975) were studied. The cell proliferation and survival were investigated via cell counting, MTT and colony-formation assays. Cell apoptosis and cell cycle were examined using annexin V-PE/7-AAD and PI staining assays, respectively. The dual-luciferase reporter assay was used to verify post-transcriptional regulation of heme oxygenase-1 (HO-1) by miR-1304. CRISPR/Cas9 was used to deplete endogenous miR-1304. Overexpression of MiR-1304 significantly decreased the number and viability of NSCLC cells and colony formation, and induced cell apoptosis and G0/G1 phase cell cycle arrest. HO-1 was demonstrated to be a direct target of miR-1304 in NSCLC cells. Restoration of HO-1 expression by hemin (20 μmol/L) abolished the inhibition of miR-1304 on cell growth and rescued miR-1304-induced apoptosis in A549 cells. Suppression of endogenous miR-1304 with anti-1304 significantly increased HO-1 expression and promoted cell growth and survival in A549 cells. In 17 human NSCLC tissue samples, miR-1304 expression was significantly decreased, while HO-1 expression was significantly increased as compared to normal lung tissues. MicroRNA-1304 is a tumor suppressor and HO-1 is its direct target in NSCLC. The results suggest the potential for miR-1304 as a therapeutic target for NSCLC.